An Eye Drug Failed Its Main Test — Now Its Maker Wants to Exclude Nine Patients
DURAVYU didn't hit its primary goal in the LUGANO trial. EyePoint says nine patients who lost vision from unrelated causes skewed the result. Not one patient in the comparison group had the same problem.